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BRD4Background: Intimal hyperplasia is a common cause of many vasculopathies. There has been a recent surge of
interest in the bromo and extra-terminal (BET) epigenetic “readers” including BRD4 since the serendipitous
discovery of JQ1(+), an inhibitor speciﬁc to the seemingly undruggable BET bromodomains. The role of the
BET family in the development of intimal hyperplasia is not known.
Methods:We investigated the effect of BET inhibition on intimal hyperplasia using a rat balloon angioplastymodel.
Results:While BRD4 was dramatically up-regulated in the rat and human hyperplastic neointima, blocking BET
bromodomains with JQ1(+) diminished neointima in rats. Knocking down BRD4 with siRNA, or treatment with
JQ1(+) but not the inactive enantiomer JQ1(−), abrogated platelet-derived growth factor (PDGF-BB)-
stimulated proliferation and migration of primary rat aortic smooth muscle cells. This inhibitory effect of
JQ1(+) was reproducible in primary human aortic smooth muscle cells. In human aortic endothelial cells,
JQ1(+) prevented cytokine-induced apoptosis and impairment of cell migration. Furthermore, either BRD4
siRNA or JQ1(+) but not JQ1(−), substantially down-regulated PDGF receptor-α which, in JQ1(+)-treated
arteries versus vehicle control, was also reduced.
Conclusions: Blocking BET bromodomains mitigates neointima formation, suggesting an epigenetic approach for
effective prevention of intimal hyperplasia and associated vascular diseases.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Intimal hyperplasia (IH) produces vascular lumen re-narrowing or
restenosis, leading to failure of angioplasty or bypass commonly per-
formed to treat cardiovascular disease.Without preventive intervention
the incidence of restenosis can reach ~30–50% within 6 months after
surgery (Jukema et al., 2012). While the etiology of IH is multifactorial,
at its center is the transition of vascular smooth muscle cells (SMCs)
from quiescence to a proliferative and migratory cell state (Alexander
and Owens, 2012). It has become recognized that this SMC phenotypic
transition or switching is prompted by abnormalities in chromatin re-
modeling (Alexander and Owens, 2012). Aside from epigenetic writersmooth muscle cell; EC, vascular
n family of epigenetic readers;
ember; JQ1(+), a BET-speciﬁc
, platelet-derived growth factor.
iversity of Wisconsin School of
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. This is an open access article under(histone acetyl transferases) and erasers (histone deacetylases), there
has emerged a new family of epigenetic readers, the bromo and extra-
terminal domain (BET) proteins (Gillette and Hill, 2015).
The BET family comprises BRDT, BRD2, BRD3, and BRD4 (Shi and
Vakoc, 2014). BRDT is testis-speciﬁc and hence irrelevant in the vascular
system. Each BET protein contains tandem bromodomains that “read”
(or bind) acetylated histones. In contrast to BRD2 and BRD3, BRD4
is unique in that it has a C-terminal domain to recruit the positive
transcription elongation factor (p-TEFb) to paused RNA polymerase II
activating transcriptional elongation (so-called pause release) (Shi
and Vakoc, 2014; Kanno et al., 2014). Thus BRD4 “translates” chromatin
remodeling to gene transcription.
BET epigenetic readers were traditionally deemed undruggable.
However, a recent serendipitous discovery of a BET-speciﬁc bromo-
domain blocker (JQ1(+)) (Filippakopoulos et al., 2010), and subse-
quently its derivatives, have dramatically changed this view(Wang
and Filippakopoulos, 2015). Intriguingly, blockade of BRD4— a general
transcription co-activator, does not suppress gene transcription globally,
but rather, selectively inhibits the expression of a subset of overac-
tive genes that are often associated with disease states (Wang and
Filippakopoulos, 2015, Anand et al., 2013). The key of this selectivitythe CC BY license (http://creativecommons.org/licenses/by/4.0/).
1651B. Wang et al. / EBioMedicine 2 (2015) 1650–1661may lie in clusters of transcription enhancers termed super-enhancers
(Loven et al., 2013). Upon pathogenic stimulation, super-enhancers re-
assemble at a deﬁned set of genes and recruit BRD4 for transcriptional
activation of these genes driving cell state transition (Amaral and
Bannister, 2014; Brown et al., 2014). This notion has gained strong sup-
port from chemical genetic studies using JQ1(+) to inhibit cancer cell
proliferation (Asangani et al., 2014; Loven et al., 2013), cardiomyocyte
hypertrophy (Anand et al., 2013), and endothelial cell inﬂammation
(Brown et al., 2014).
The primary cause of IH is the phenotypic transition of SMCs from a
quiescent to a proliferative/migratory cell state, which involves active
transcription of a subset of genes, such as growth factors and cytokines
and/or their receptors (Alexander and Owens, 2012). We thus hypoth-
esized that the BET epigenetic readers may play a critical role in this cell
state transition (Wang et al., 2015), in particular, activation of the
platelet-derived growth factor (PDGF) pathway — the most potent
stimulant for vascular SMC proliferation and migration (Heldin and
Westermark, 1999). Blocking BET bromodomains with JQ1(+) has
exhibited high preclinical efﬁcacy in a growing number of malignancies
(Zuber et al., 2011; Delmore et al., 2011; Brown et al., 2014; Anand et al.,
2013). However, the function of the BET family in restenotic vascular
disease is not known. This study aimed to assesswhether the BET family
plays an important role in the development of IH.
2. Methods
2.1. Rat Carotid Artery Balloon Angioplasty Model and Peri-adventitial
Administration of JQ1(+)
All animal studies conform to the Guide for the Care and Use of Labo-
ratory Animals (National Institutes of Health publication No. 85–23,
1996 revision) and protocols approved by the Institutional Animal
Care andUse Committee at theUniversity ofWisconsin. Institutional re-
view board (IRB) approval has been obtained for use of human samples.
2.2. Rat Carotid Artery Balloon Angioplasty and Peri-adventitial JQ1(+)
Administration
Carotid artery balloon angioplasty was performed in male Sprague–
Dawley rats (Charles River; 300–330 g) as previously described (Guo
et al., 2014). Brieﬂy, rats were anesthetized with isoﬂurane (5% for
inducing and 2.5% for maintaining anesthesia). A longitudinal incision
was made in the neck and carotid arteries were exposed. A 2-F balloon
catheter (Edwards Lifesciences, Irvine, CA) was inserted through an
arteriotomy on the left external carotid artery. To produce arterial injury,
the balloonwas inﬂated at a pressure of 2 atmandwithdrawn to the carot-
id bifurcation and this actionwas repeated three times. The external carot-
id artery was then permanently ligated, and blood ﬂowwas resumed.
Balloon angioplasty was performed for two sets of experiments.
(1) Time course. The left carotid arteries were collected at days 3, 7,
and 14 post-angioplasty for immunostaining of BRD4; the uninjured
right carotid arteries served as control. (2) JQ1(+) treatment. Immedi-
ately following angioplasty, JQ1(+)(CAS 1268524-70-4, CaymanChem-
ical, MI) (For compound structure, see publication) (Filippakopoulos
et al., 2010) or DMSO (vehicle control) dissolved in F-127 Pluronic gel
was applied to the outside of the balloon-injured segment of the carotid
artery (Guo et al., 2014). For administration of JQ1(+), we used two
doses (100 μg or 500 μg per rat) (Wang et al., 2015) which are believed
to be well below toxic levels because even a dose of 50 mg/kg body
weight did not show toxicity in previous studies (Asangani et al.,
2014). JQ1(+) from a DMSO stock was dissolved in 25% F-127 Pluronic
gel (Sigma-Aldrich) to a ﬁnal volume of 300 μl (JQ1 concentration in
the gel: 0.72 mM or 3.6 mM), which was then applied to the outside
of the injured segment of the carotid artery. In the control group,
equal volume of DMSO vehicle mixed with Pluronic gel was applied.
This perivascular approach has been proven effective in the delivery ofsmall-molecule drugs or even nanoparticles into the injured arterial
wall (Shi et al., 2014). Twoweeks after balloon angioplasty, common ca-
rotid arteries were collected from anesthetized animals (under 2.5%
isoﬂurane) following perfusion ﬁxation at a physiological pressure of
100 mm Hg (Guo et al., 2014). The animals were then euthanized in a
CO2 chamber.
2.3. Morphometric Analysis of Intimal Hyperplasia (IH)
Parafﬁn sections (5 μm thick) were excised from carotid arteries
at equally spaced intervals and then Van Gieson stained for morpho-
metric analysis, as described in our previous reports (Guo et al., 2014).
Planimetric parameters as follows were measured on the sections and
calculated using Image J: area inside external elastic lamina (EEL
area), area inside internal elastic lamina (IEL area), lumen area, intima
area (=IEL area – lumen area), and media area (=EEL area – IEL area).
Intimal hyperplasia was quantiﬁed as a ratio of intima area versus
media area. Measurements were performed by a student blinded to the
experimental conditions using 3–6 sections from each of 4 rats treated
with either vehicle (DMSO) or JQ1(+). The data from all sections were
pooled to generate the mean for each animal. The means from all the
animals in each treatment group were then averaged, and the standard
error of the mean (SEM) was calculated.
2.4. Immunohistochemistry for Assessment of BRD4, PDGFRα, and PCNA
Expression in Rat and Human Arteries and Veins
Immunostaining was performed on rat carotid artery sections fol-
lowing our published methods (Guo et al., 2014). Brieﬂy, the sections
were ﬁrst incubated with each of the primary antibodies for 1 h with a
dilution ratio as follows: rabbit anti-BRD4 (Abcam, Cambridge, MA),
1:150; rabbit anti-PDGFRα (Bolster), 1:200; rabbit anti-PCNA (Santa
Cruz), 1:200. The sections were then incubated with the ImmPRESS
HRP-conjugated goat-anti-rabbit secondary antibody (Vector Laborato-
ries, 1:200), followed by visualization with 3, 3-diaminobenzidine
(DAB). The slides were counterstained with hematoxylin. The number
of positively stained cellswas counted on 8-bit binary images converted
(by Image J) from the pictures of immunostained sections and normal-
ized by the high power microscopic ﬁeld (HPF). Cell counting was
performed by a student blinded to experimental conditions. In each
experimental group (DMSO control or JQ1(+) treatment), at least 8
sections from each of 4 animals were used. The data from all sections
were pooled to generate the mean for each animal. The means from
all the animals in each experimental group were then averaged, and
the standard error of the mean (SEM) was calculated. The same immu-
nohistochemistry conditionswere applied to the human artery and vein
samples. Hematoxylin counter-staining is not presented in Fig. 1
because we have found that intense counter-staining (blue) tends to
overwrite the BRD4 immunostaining (brown) which is also localized
in the nucleus.
2.5. Primary Vascular Smooth Muscle Cell and Endothelial Cell Cultures
Rat aortic vascular SMCs were isolated from the thoracoabdominal
aorta of male Sprague–Dawley rats based on a protocol using an enzy-
matic dissociation method and cultured in Dulbecco modiﬁed Eagle
low glucose medium (Gibco, Carlsbad, CA) containing 10% fetal bovine
serum (FBS) (Guo et al., 2014). Human primary aortic smooth muscle
cells and human primary aortic endothelial cells were purchased from
Lonza and cultured in SmGM-2 complete medium containing 5% FBS
and EGM-2 complete medium containing 2% FBS, respectively (Goel
et al., 2014). Cells between passage 5 and 7 were used for all experi-
ments and maintained at 37 °C with 5% CO2 (Guo et al., 2014). For cell
culture expansion, 0.25% Trypsin was used for detachment of rat and
human SMCs, while Accutase (Lifetechnologies, Carlsbad, CA) was
used for human ECs.
Fig. 1.Up-regulation of BRD4 in the neointima of injured rat carotid arteries and in human vein and artery grafts. A. Immunostaining of rat carotid artery sections showing increase of BRD4
positive cells at days 3, 7, and 14 after balloon angioplasty versus uninjured arteries. “Negative staining” refers to background control without using a primary antibody. Quantiﬁcation:
mean ± SEM; n = 3 animals at each time point; *P b 0.05 compared to uninjured control. Arrowhead: internal elastic lamina (IEL); arrow: external elastic lamina (EEL). Neointima is
deﬁned between lumen and IEL. Scale bar: 50 μm. B. Immunohistochemistry showing increase of BRD4 in the neointima of human saphenous vein and internal mammary artery grafts
versus normal vessels. Arrowhead: IEL. Scale bar: 50 μm.
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To study the effect of JQ1(+) on the proliferation of rat as well
as human aortic SMCs, we used both a Cell Proliferation BrdU ELISA
(colorimetric) Kit (Roche Applied Science, Indianapolis, IN) and a
CellTiter-Glo Luminescent Cell Viability kit (Promega, Madison,WI) fol-
lowing manufacturer instructions. SMCs were seeded in 96-well plates
at a density of 4000 cells (BrdU assay) or 2000 cells (CellTiter-Gloassay) per well with a ﬁnal volume of 200 μl, and starved for 24 h in
DMEM (for rat cells) or SmBM-2 basal medium (for human cells) con-
taining 0.5% FBS. Cells were then pretreated with a series of concentra-
tions of JQ(+)1, JQ(−)1, or an equal volume of vehicle control (DMSO)
for 1 h in fresh starvation medium prior to PDGF-BB (human recombi-
nant, R&D Systems Inc., MN) mitogenic stimulation (ﬁnal 10 ng/ml).
After PDGF-BB treatment for 22 h, cells were labeled with BrdU by a
2-h incubation at 37 °C, and then ﬁxed with a FixDenat solution for
1653B. Wang et al. / EBioMedicine 2 (2015) 1650–166130 min, followed by a 90-min incubation at room temperature with
an anti-BrdU-POD antibody (1:100 dilution). After washing with PBS
for 3 times, substratewas added. Plateswere incubated at room temper-
ature for 30 min, and then colorimetric signals were measured on
a FlexStation 3 Benchtop Multi-Mode Microplate Reader (Molecular
Devices, Sunnyvale, CA) at 370 nm with a reference wavelength of
492 nm.
Cell viability assay was performed as described in our previous
report (Guo et al., 2014). Brieﬂy, 96 h after PDGF-BB treatment, plates
were decanted and re-ﬁlled with 50 μl CellTiter-Glo reagent/50 μl PBS
per well. Plates were incubated at room temperature for 10 min and
then read in a FlexStation 3 Benchtop Multi-Mode Microplate Reader
(Molecular Devices, Sunnyvale, CA) using a 250 ms integration.
2.7. Scratch and Transwell Migration Assays
Scratch (wound healing) assay was performed as described in our
previous report (Guo et al., 2014). Brieﬂy, SMCs were cultured to
a 90% conﬂuency in 6-well plates and then starved for 24 h in DMEM
medium containing 0.5% FBS, which was supplemented with 1 μM
JQ1(+),1 μM JQ1(−), or equal volume of DMSO. A sterile pipette tip
was used to generate an ~1 mm cell-free gap. Dislodged cells were
washed awaywith PBS. Plates were then reﬁlledwithmedium contain-
ing 10 ng/ml PDGF-BB and incubated for 24 h. At the end of the treat-
ment, for illumination of the cells, Calcein AM was added at a ﬁnal
concentration of 2 μM and incubated for 30 min. After 3 times of wash
with PBS, images were taken, and cell migration was quantiﬁed by
Image J based on the change in the width of the cell-free gap before
and after PDGF-BB stimulation. For Transwell assay, SMCs were starved
for 24 h in DMEM medium containing 0.5% FBS, and then seeded at a
density of 20,000/well in the upper chamber of Transwell Permeable
Supports (or Inserts) (8 μm pore size, Corning, NY) placed in 24-well
plates. Cells were pre-incubated with 1 μM JQ1(+), JQ1(−), or vehicle
(DMSO) for 24 h prior to the stimulation of chemotaxis with 10 ng/ml
PDGF-BB, which was added to the lower chamber at a ﬁnal concentra-
tion of 10 ng/ml. Inserts were harvested 24 h post stimulation and
ﬁxed in 70% ethanol at −20 °C for 30 min. Pre-wetted cotton swaps
were used to gently scrape remaining cells in the upper chamber of
inserts, followed by staining the cells on the lower surface of the insert
in hematoxylin solution for 30 min at room temperature. The upper
chamber of the inserts was swapped again and rinsed in PBS twice.
After air-drying the inserts for 30 min, the polyester membranes were
harvested using a scalpel andmounted on glass slides using 90% glycerol.
Imageswere then taken for quantiﬁcation of the cells thatmigrated from
the upper chamber across the membrane to the lower surface.
2.8. Caspase-Glo 3/7 Assay for Endothelial Cell Apoptosis
Caspase-Glo 3/7 assay (Promega, Madison, WI) was used to deter-
mine the relative activity of caspase-3/7 according to manufacturer's
instructions. Brieﬂy, human aortic endothelial cells were seeded in
96-well plates at a density of 8000 cells/well and starved in 1% FBS
medium for 24 h. Before stimulation with human recombinant TNFα
or IL-1β (R&D Systems)(ﬁnal concentration 20 ng/ml), cells were
pretreated with 100 nM JQ1(+) or vehicle control for 24 h. Four hours
after cytokine treatment, plates were decanted and re-ﬁlled with 50 μl
Caspase-Glo 3/7 reagent and 50 μl PBS per well. Plates were incubated
at room temperature for 1 h and then read in a FlexStation 3 Benchtop
Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale, CA).
2.9. siRNA Knockdown
Lentiviruses for expression of scrambled or rat BRD-speciﬁc siRNAs
were packaged using a three-plasmid expression system (piLenti-
siRNA-GFP, psPAX2 and pMD2.G). The piLenti-siRNA-GFP vectors for
expression of a scrambled siRNA or an siRNA speciﬁc for rat BRD2,BRD3, or BRD4 were purchased from Applied Biological Materials Inc.
(Canada). The target sequence of the most efﬁcient BRD4 siRNA is
GCGAATCTAGCTCCTCTGACAGTGAAGAC. For each of BRD2 and BRD4
two siRNAs were used. BRD2 siRNA#134: CCACAATGGC TTCTGTACCA
GCTTTACAA; #1141: CCACAATGGCTTCTGTACCAGCTTTACAA. BRD3
siRNA #295: AGTGAGTGTAT GCAGGACTTCAACACCAT; #355: ACAGAT
GACATAGT GCTAATGGCCCAGGC. The psPAX2 and pMD2.G plasmids
were kindly provided byDr.Ming-Liang Chu (GuizhouRenminHospital,
China). The 3 plasmidswere co-transfected into HEK293T cells in DMEM
medium containing 10% FBS using a JetPrime Polyplus-transfection
reagent (Polyplus-transfection Inc., New York, NY) following the
manufacturer's protocol. After transfection for 24h, themediumcontain-
ing transfection reagents was replaced with fresh DMEM medium con-
taining 10% FBS. The culture medium was collected after 24 h
incubation and the collections containing packaged lentivirus were
passed through a 0.45 μm ﬁlter (EMD Millipore, MA), and then concen-
trated and titrated using Lenti-X™ Concentrator and Lenti-X™ qRT-PCR
Titration Kit (Clontech Laboratories, Inc., Mountain View, CA), respec-
tively. The lentivirus preparationwas then applied to the SMC culture to-
gether with 8 μg/ml polybrene. Infected cells were recovered in fresh
DMEM medium containing 10% FBS for 24 h and then used in experi-
ments of proliferation or Western blotting.
2.10. Real-time Quantitative PCR (qRT-PCR)
mRNAwas isolated from collected cells using TRIzol (Qiagen, Valen-
cia, CA) following themanufacturer's instructions. PuriﬁedmRNA (1 μg)
was used for the ﬁrst-strand cDNA synthesis using iScript cDNA synthe-
sis kit (Bio-Rad) and quantitative RT-PCRwas performed using the 7500
Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA). Each
cDNA template was ampliﬁed in triplicates using SYBR Green PCR
Master Mix (Applied Biosystems, Carlsbad, CA) with the following
primers: Rat BRD4, Forward CTGCCAGTAATGGGGGATGG, Reverse
ATTGGTGCTGGCTGCATTTG. Rat BRD3, Forward TCCAGGATCAGCTGTT
GAATGT, Reverse GCTGTGGTTGTGCTATTGGC. Rat BRD2, Forward GGGT
CTGCCGGATTATCACA, Reverse GCCCCCTTCTTATGGCTGTT. Rat PDGFRα,
forward GCC TCC ATT CTG GAG CTT GT, reverse AGC TCT CTG TTC CCA
ATG CC. Rat PDGFRβ, forward ATG AGT CAT CTC GGA CCC CA, reverse
TCA GGG GCA GAT GGG ACA TA. Rat GAPDH, forward GAC ATG CCG
CCT GGA GAA AC, reverse AGC CCA GGA TGC CCT TTA GT.
2.11. Western blotting for Evaluation of Protein Levels
SMCs were lysed in RIPA buffer containing protease inhibitors
(50 mM Tris, 150 mM NaCl, 1% Nonidet P-40, 0.1% sodium dodecyl
sulfate, and 10 μg/ml aprotinin). Protein concentrations of cell lysates
were determined using a Bio-RadDC™ Protein Assay kit. Approximately
15–30 μg of proteins from each sample were separated on 4–20% Mini-
PROTEAN TGX precast gels (Bio-Rad) and transferred to a PVDF mem-
brane. Proteins of interest were detected by immunoblotting using the
following primary antibodies and dilution ratios: Rabbit anti-BRD4
(1:1000) from Abcam (ab128874), rabbit anti-PDGFRα (1:1000) from
Cell Signaling technology (3164 s), rabbit anti-PDGFRβ (1:200) from
Santa Cruz (sc-432) and mouse anti-β-actin from Sigma-Aldrich. After
incubation of the blots with HRP-conjugated secondary antibodies
(1:3000 for goat anti-rabbit or 1:10,000 for goat anti-mouse, Bio-Rad),
speciﬁc protein bands on the blots were visualized by applying en-
hanced chemiluminescence reagents (Pierce) and then recorded with
a LAS-4000 Mini imager (GE, Piscataway NJ). Band intensity was quan-
tiﬁed using ImageJ.
2.12. Statistical Analysis
Data are presented as mean ± standard error of the mean (SEM).
Statistical analysis was conducted using two-tailed unpaired Student's
1654 B. Wang et al. / EBioMedicine 2 (2015) 1650–1661t-test. Data are considered statistically signiﬁcant when a P value is
b0.05.3. Results
3.1. Epigenetic Reader BRD4 is Dramatically Up-regulated in the Neointima
of Injured Rat Carotid Arteries as well as Human Vein and Artery Grafts
BRD4 is the best characterized BET member and has been shown to
play a pivotal role in several disease states (Anand et al., 2013; Wang
and Filippakopoulos, 2015). It is a unique BETmember in that it is asso-
ciated with super-enhancers and its C-terminal domain facilitates
the recruitment of the positive transcription elongation factor p-TEFb
to activate RNA polymerase II (Anand et al., 2013; Kanno et al., 2014).
We thus set out to investigate the role of BET family in intimal hyperpla-
sia (IH) by assessing BRD4 expression in the rat carotid artery in a bal-
loon angioplasty model (Guo et al., 2014). While the ratio of BRD4-
positive versus total cells in the media of uninjured arteries remained
at a basal level of ~10%, this ratio increased to 50% at day 3 after balloon
injury (Fig. 1A). Interestingly,while the expression of BRD4 in themedia
declined after day 3, concomitantly BRD4-positive cells dramatically
increased in the neointima with a ratio of 85% versus total cells at
day 7, and remained at 55% at day 14. A pronounced increase of BRD4
was also observed in the neointima of human saphenous vein and inter-
nal mammary artery grafts versus normal vessels lacking neointima
(Fig. 1B and supplemental Figure S1), suggesting clinical relevance of
our ﬁndings. These results demonstrate that the epigenetic reader
BRD4 is dramatically up-regulated following the development of neoin-
tima in rat as well as human blood vessels, implicating its involvement
in the process of IH.Fig. 2. Inhibition of intimal hyperplasia by treatment with JQ1(+) in balloon-injured rat carotid
carotid arteries compared to vehicle control 14 days after injury. Arrowhead: IEL; arrow: EEL. B
mean ± SEM; n = 4 animals; *P b 0.05 versus vehicle control.3.2. Blocking BET Bromodomains with JQ1(+) Effectively Mitigates IH in
Balloon-injured Rat Carotid Arteries
We then investigated the function of the BET family in the develop-
ment of IH using the ﬁrst-in-class BET-speciﬁc inhibitor, JQ1(+), which
was recently discovered (Filippakopoulos et al., 2010). An acetyl lysine-
binding pocket in the bromodomain is unique to the BET proteins.
JQ1(+) occludes this pocket by mimicking the acetyl moiety and is
thus highly speciﬁc for the BET family (Kanno et al., 2014). In our
study (Fig. 2), treatment by peri-adventitial administration of JQ1(+)
(500 μg per rat) reduced IH (I/M ratio) by 75% and enlarged the
lumen by 60% versus vehicle control at day 14 post injury. A lower
dose (100 μg per rat) produced a numerical decrease of IH which was
not statistically signiﬁcant. The vessel size measured by EEL (external
elastic lamina) length was unaltered with either dose. These results
demonstrate that blocking BET epigenetic reader activity can effectively
mitigate IH, indicating an important role of this family in the formation
of hyperplastic neointima.
3.3. BET Inhibition Mitigates SMC Proliferation and Migration In Vitro as
well as In Vivo
It has been well documented that proliferation as well as migration
of vascular SMCs are major contributors to IH (Alexander and Owens,
2012; Jukema et al., 2012). In response to vascular injury, quiescent
SMCs are activated by cytokines or growth factors, migrate into the
subintimal space and proliferate, forming highly cellular neointima
(Jukema et al., 2012). PDGF signaling is known to be the most potent
stimulant for vascular SMC proliferation and migration (Heldin and
Westermark, 1999). In our experiments, PDGF-BB stimulation increased
BRD4 protein levels (Figure S2). We therefore determined the effect ofarteries. A. Van Gieson-stained sections showing reduced neointima in JQ1(+)-treated rat
. Quantiﬁcation of IH (intima/media area ratio), lumen area, and EEL length is presented as
1655B. Wang et al. / EBioMedicine 2 (2015) 1650–1661JQ1(+) on the phenotypic transition of primary rat aortic SMCs stimu-
lated by PDGF-BB. We found that the enantiomer JQ1(−), which is
identical to JQ1(+) except being a stereoisomer, had no effect on
PDGF-BB-stimulated rat aortic SMC proliferation throughout a range
of concentrations from 5 nM to 10 μM. In contrast, JQ1(+) produced a
pronounced inhibitory effect in a dose-dependent manner (Fig. 3A).
An inhibitory effect of JQ1(+) on SMC proliferation was reproducible
using human primary aortic SMCs (Fig. 3B). Importantly, we conﬁrmed
that JQ1(+)-treated rat carotid arteries at post-injury day 14 had
fewer proliferating cells (PCNA-staining) compared to vehicle control
(Fig. 3C). We also found that treatment with 1 μM JQ1(+) inhibited
SMC migration (~60%) compared to vehicle control whereas JQ1(−)
had no effect (Figs. 4 and S3). In support of an important role of BRD4,
knocking down BRD4 using an siRNA (Fig. 5, A and B) markedly
inhibited rat SMC proliferation (Fig. 5C) as well as migration (Figs. 5D
and S4). A speciﬁc BRD4 knockdown using BRD4 siRNA was con-
ﬁrmed by the lack of changes in BRD2 and BRD3 mRNA levels (Fig. 5A).
These results indicate that blocking BET bromo-domains inhibits SMCFig. 3. Inhibition of rat and human aortic smooth muscle cell proliferation by treatment with JQ
primary rat (A) and human (B) aortic SMCs, by JQ1(+) but not JQ1(−). Proliferation was mea
mean± SEM; n= 3 independent experiments. C. Immunostaining of PCNA showing reduced p
14 days after injury. Arrowhead: IEL; arrow: EEL. “Negative staining” refers to the background
*P b 0.05 versus vehicle control. HPF: high power ﬁeld. Scale bar: 50 μm.proliferation andmigration,which at least partly accounts for the abroga-
tion of IH after JQ1(+) treatment (Fig. 2).
3.4. BET Inhibition Down-regulates PDGFRα in Cultured SMCs as well as in
Balloon-injured Rat Carotid Arteries
Inasmuch as inhibiting BET activity abrogates PDGF-BB-stimulated
SMC proliferation and migration, we focused on PDGF receptors
(PDGFRs) as a potential molecular mechanism responsible for the func-
tion of the BET family in the SMC phenotypic transition. While 100 nM
JQ1(+) reduced PDGFRα mRNA approximately 50% (Fig. 6A), 1 μM
JQ1(+), a concentration that produced marked inhibition of both SMC
proliferation and migration (see Figs. 3 and 4), almost completely
eliminated PDGFRα mRNA and also greatly reduced PDGFRα protein
(by 70%). PDGFRβmRNA but not protein was reduced under the same
conditions (Figure S5). Further supporting a BET control over PDGFR
expression, 1 μM JQ1(+) signiﬁcantly suppressed PDGF-BB-stimulated
ERK phosphorylation (Fig. 6B)— awell-documented event downstream1(+). A and B. Dose responses to JQ1 enantiomers showing inhibition of proliferation of
sured by CellTiter-Glo assay or BrdU assay 24 h after PDGF-BB stimulation. Quantiﬁcation:
roliferating cells in JQ1(+)-treated (500 μg per rat) carotid arteries versus vehicle control
control without using a primary antibody. Quantiﬁcation: mean ± SEM; n = 4 animals;
Fig. 4. Inhibition of rat smoothmuscle cellmigration by treatmentwith JQ1(+). Scratch assay (A) and Transwell assay (B) showing inhibition of rat SMCmigration by 1 μM JQ1(+) but not
JQ1(−) at 24 h after PDGF-BB stimulation. Dashed line marks the cell-free gap at 0 h after scratch. Quantiﬁcation: mean ± SEM; n = 3; *P b 0.05 versus vehicle control.
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ed by the lack of an effect of the JQ1(−) enantiomer on PDGFRs. Aswell,
an important role of BRD4 for the control of PDGFRα expression was
supported by up to 60% decrease of PDGFRα protein following siRNA
knockdown of BRD4 (Fig. 6C). Furthermore, immunohistochemistry
showed less PDGFRα staining in JQ1(+)-treated rat arteries compared
to vehicle control at 14 days post injury (Fig. 7A). Interestingly, we
found a pattern of post-injury up-regulation of PDGFRα similar to that
of BRD4— increased at day 3 in the media, peaked at day 7 in the neo-
intima, and still maintained at high levels at day 14 in the neointima
(Figure S6). In addition, we also observed conspicuously more PDGFRα
staining in the neointima of human disease vein and artery grafts com-
pared to normal vessels without hyperplastic neointima (Fig. 7B). These
results support a prominent BET control over PDGFRα expression
in vitro and in vivo.3.5. BET Inhibition Rescues Vascular Endothelial Cells from
Pro-inﬂammatory Cytokine-induced Dysfunction
Amajor drawback of the drugs clinically used in drug-eluting stents
(e.g. rapamycin andpaclitaxel) for prevention of restenosis is their dam-
aging effects on endothelial cells (ECs) that lead to late-stent thrombosis
and sudden death (Iakovou et al., 2005; Inoue et al., 2011). On the other
hand, reports of anti-restenotic agents that can preserve EC functions
are scarce (Goel et al., 2014).We thus tested the impact of JQ1(+) treat-
ment on human primary aortic ECs. It has been well established that
either of the two pro-inﬂammatory cytokines, TNFα and IL-1β, induces
EC apoptosis and inhibits EC migration (Simon, 2012). In our experi-
ment, whereas each of TNFα and IL-1β stimulated Caspase-dependent
EC apoptosis by 3–4 fold compared to vehicle control, incubation of
the cells with 100 nM JQ1(+) completely prevented this cytokine-
induced apoptosis (Fig. 8A). In a separate experiment, whereas either
TNFα or IL-1β inhibited EC migration, as determined by scratch assay,
incubation with 100 nM JQ(+) restored EC migration (Figs. 8B and S7).
These results indicate that BET inhibition protects ECs from functional
damage inﬂicted by pro-inﬂammatory cytokines.4. Discussion
While the critical role of epigenetic regulators in disease develop-
ment is becomingwidely recognized, epigenetic regulations in vascular
diseases, in particular restenosis, are less well understood (Alexander
and Owens, 2012). The BET family is a class of epigenetic regulators
that “read” histone acetylation and “translate” it into transcriptional
activation (Shi and Vakoc, 2014). The dictating role of the BET family
in cell identity (Di Micco et al., 2014) as well as cell state transition
(Brown et al., 2014) is beginning to be unveiled thanks to the recent
discovery of small molecule inhibitors that speciﬁcally block the
bromodomain/acetyl-lysine interaction (Filippakopoulos and Knapp,
2014). These advances have opened fresh opportunities for thera-
peutic targeting of BET epigenetic “readers”. However, the role of
the BET family in the development of IH — the primary cause of
many vasculopathies — is not known (Wang et al., 2015). Here we
ﬁnd that inhibiting the BET family with JQ1(+) or knocking down
BRD4 alone abrogates the neointima-promoting SMC transition to
a migratory/proliferative cell state while protecting vascular ECs
from pro-inﬂammatory cytokine-induced dysfunction. We have fur-
ther identiﬁed that either BET inhibition or BRD4 knockdown results in
down-regulation of PDGFRα, a prominent activator of SMCproliferation
andmigration. Importantly, using the rat balloon angioplastymodel, we
ﬁnd that blocking BET bromodomains with JQ1(+) diminished IH.
Thus, our results highlight a potential of targeting the BET family for
prevention of IH-associated vascular diseases such as restenosis.
Aside from the pathogenic SMC transition to amigratory/proliferative
cell state, dysfunctionof ECs also critically contributes to IH (Simon, 2012;
Inoue et al., 2011). On the one hand, normal endothelium serving as a
protective inner lining shields medial SMCs from various blood-borne
stimuli, e.g. growth factors and cytokines, which otherwise stimulate
SMC phenotypic transition leading to IH. On the other hand, when
activated by inﬂammatory stimuli, ECs become dysfunctional. They
undergo apoptosis and recruit leukocytes, leading to release of inﬂam-
matory cytokines that exacerbate SMC pathology and IH. Therefore, the
ideal anti-restenotic agent would impair SMC proliferation/migration
without affecting EC normal physiology, allowing re-establishment of
Fig. 5. Inhibition of rat smoothmuscle cell proliferation andmigration by siRNA knockdown of BRD4. A and B. Speciﬁc siRNA knockdownof BRD4 indicated byRT-PCR (A) andWestern blot
(B). C andD. Inhibition of PDGF-BB stimulated (for 24h) rat SMCproliferation (BrdUassay)(C) andmigration (scratch assay)(D), by BRD4 siRNA knockdown.Quantiﬁcation:mean±SEM;
n = 3; *P b 0.05 versus scrambled siRNA control.
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an atherosclerotic artery (Goel et al., 2014). Unfortunately, the clinically
applied anti-restenotic drugs (rapamycin or paclitaxel coated on stents)
impair re-endothelialization (Inoue et al., 2011; Wessely et al., 2006),
leading to stent thrombosis which is associated with ~50% mortality
(Iakovou et al., 2005). Agents that inhibit SMC proliferation/migration
but preserve EC function have only been scarcely reported, and none
has reached clinical trials for prevention of restenosis (Goel et al.,
2014). Remarkably, we found that instead of harming ECs, JQ1(+)
protected human aortic ECs from TNFα or IL-1β-induced dysfunction
(apoptosis and impaired migration). This result is consistent with the
ﬁnding of Brown et al., i.e., JQ1(+) suppresses TNFα-induced leukoctyerecruitment by human umbilical vein ECs(Brown et al., 2014). In
addition, our data indicate that treatment with JQ1(+) reduces IH
without causing shrinkage of the vessel size (termed constrictive
remodeling) which, aside from IH, is another important contributor
to restenosis (Guo et al., 2014; Goel et al., 2012). Therefore, targeting
BET epigenetic readers appears to be an attractive strategy for preven-
tion of restenosis. Accordantly, in preclinical studies, BET inhibitors
have shown extremely low-toxicity (Zuber et al., 2011; Asangani
et al., 2014) but high efﬁcacy in treating leukemia (Zuber et al., 2011),
multiple myeloma (Delmore et al., 2011) and heart failure (Anand
et al., 2013). Some of the inhibitors have entered clinical trials (Wang
and Filippakopoulos, 2015).
Fig. 6. Down-regulation of PDGFRα in vitro by treatment with JQ1(+) or siRNA knock-
down of BRD4. A. Determination of PDGFRα mRNA (RT-PCR) and protein (Western
blot). mRNA was determined at 6 h and protein was determined at 24 h after treatment
with JQ1(+). Quantiﬁcation:mean± SEM; n=3; *P b 0.05 versus vehicle control. B. Inhi-
bition of ERK phosphorylation in SMCs treated with JQ1(+). In order to conﬁrm the effect
of JQ1(+) on PDGFR expression, phosphor-ERK, which is a well-established downstream
effector and hence a surrogate of PDGFR activation, was determined. Rat aortic SMCs
were pretreated with 1 μM JQ1(+), JQ1(−), or equal volume of DMSO for 48 h in starva-
tion medium, as described in Methods, and then PDGF-BB was added (ﬁnal 10 ng/ml)
for stimulation of ERK phosphorylation. Cells were harvested after 15 min and used
for Western blotting determinations. Quantiﬁcation: mean ± SEM; n = 3; *P b 0.05.
C. PDGFRα down-regulation by BRD4 siRNA. Quantiﬁcation: mean ± SEM; n = 3;
*P b 0.05 versus scrambled siRNA control.
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BET family. JQ1(+) is highly speciﬁc to the BET family but binds to the
bromodomains of all family members with similar afﬁnities (Baud
et al., 2014). Although we cannot rule out possible contributions ofBRD2 and BRD3, our data point to a prominent role of BRD4 in
governing SMC proliferation and migration and PDGFRα expression.
Evidence includes the following: 1) While speciﬁc knockdown of
BRD4 using an siRNA reduced SMC proliferation, migration, as well as
PDGFRα protein to an extent similar to that of BRD4 reduction
(~60%), knockdown of BRD2 or BRD3 did not affect SMC proliferation
(Figure S8). 2) BRD4 dramatically increased in the rat carotid arterial
wall following injury, as well as in the neointima lesion of human vein
and artery grafts. 3) In response to PDGF-BB stimulation, BRD4 in-
creased within 30 min, likely due to post-translational regulation, and
showed another surge at 6 h,whichmay reﬂect de novo protein synthe-
sis. Either BRD2 or BRD3 did not show an mRNA level change over a
time course of 24 h (Figure S9). 4) Compared to other BET proteins,
BRD4 has a longer sequence containing a unique C-terminal domain
that plays a critical role in transcriptional activation by recruiting
the positive transcription elongation factor (p-TEFb) (Shi and Vakoc,
2014). 5) As reported by Brown et al., knockdown of BRD4 with an
siRNA abolished TNFα-induced EC transition to an inﬂammatory
cell state (Brown et al., 2014). 6) siRNA knockdown or gene silencing
identiﬁed BRD4 as a potential target to treat a variety of diseases, such
as leukemia (Zuber et al., 2011), heart failure (Anand et al., 2013), ovar-
ian carcinoma (Baratta et al., 2015), prostate cancer (Asangani et al.,
2014), and pulmonary disease (Khan et al., 2014). Nevertheless, future
studies to dissect the functions of BET proteins would be important
not only for mechanistic delineation but also optimization of BET-
targeted therapeutic paradigms. To this end, the CRISPR (clustered
regularly interspaced short palindromic repeats)/Cas9 genome editing
technology would be advantageous in completely depleting each of
the BET family members (Abrahimi et al., 2015). An exciting latest
development is small molecules showing a unique function of tethering
BRD4 to an E3 ubiquitin ligase for intracellular destruction, with selec-
tivity over BRD2 and BRD3 (Zengerle et al., 2015; Lu et al., 2015).
These reports represent vigorous ongoing efforts to generate selective
BET inhibitors that can discriminate different BET members, which
would facilitate breakthroughs in both mechanistic and translational
studies.
PDGF signaling is the most potent stimulant of vascular SMC
state transition to a migratory/proliferative phenotype (Heldin and
Westermark, 1999). The BET family (or BRD4) dictates cell state transi-
tion, as discoveredmost recently in ECs andmacrophages (Brown et al.,
2014). Our results from vascular SMCs indicate that PDGF receptor
expression is controlled by BET epigenetic reader activity. First, treat-
ment with JQ1(+) eliminated PDGFRα mRNA and protein. Second,
BRD4 knockdown proportionally reduced PDGFRα protein. Further-
more, the time course of post-injury PDGFRα up-regulation in the rat
carotid artery showed a pattern similar to that of BRD4. PDGFRα and
β are the only receptors for PDGF-BB (Heldin and Westermark, 1999).
While PDGFRβ has been intensively studied and shown to play a prom-
inent role in SMC pathology and IH, the speciﬁc function of PDGFRα
in this context is largely unknown (Li et al., 2011). Our data show a
dramatic increase of PDGFRα in the neointima of rat artery as well as
human disease vein and artery grafts compared to normal vessels,
implicating a role of PDGFRα in the development of IH. Consistently,
it was recently reported that PDGF-AA, which binds only to PDGFRα
but not PDGFRβ (Heldin and Westermark, 1999), activated PDGFRα
and potently stimulated human arterial SMC proliferation (Li et al.,
2011). In addition, a neutralizing antibody for PDGFRα reduced baboon
vascular SMC proliferation in a concentration-dependent manner
(Davies et al., 2000). However, anti-PDGFRβ but not anti-PDGFRα
decreased neointima either in injured arteries (Giese et al., 1999)
or polytetraﬂuoroethylene grafts in nonhuman primates (Davies
et al., 2000). The authors cautioned that the data on anti-PDGFRα
was complicated by rapid clearance of the antibody from circulation
(Davies et al., 2000). Thus, elucidation of the role of PDGFRα in neo-
intima formation awaits more sophisticated studies utilizing SMC-
speciﬁc PDGFRα knockout animals. Nevertheless, we have found a
Fig. 7.Down-regulation of PDGFRα in vivo by treatmentwith JQ1(+). A. Immunohistochemistry showing reduced PDGFRα in themedia and neointima in JQ1(+)-treated (500 μg per rat)
carotid arteries compared to vehicle control 14 days after balloon injury. Arrowhead: IEL. “Negative staining” refers to background control without using a primary antibody. Quantiﬁcation:
mean ± SEM; n = 4 animals; *P b 0.05. HPF: high power ﬁeld. Scale bar: 50 μm. B. Immunohistochemistry showing increase of PDGFRα in the neointima of human saphenous vein and
internal mammary artery grafts compared to normal vessels. Scale bar: 50 μm.
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over, differential effects of BET inhibition on the expression of
PDGFRα and PDGFRβ support a speciﬁc rather than promiscuous
BET control over gene expression. Given a critical role of PDGFRα
in caner growth and metastasis (Jechlinger et al., 2006), our ﬁnding
of BRD4 epigenetic control of PDGFRα may lend important insights
for cancer research as well.
Taken together, this study demonstrates that blocking BET epige-
netic reader activity with JQ1(+) disrupts a cell state transition of
SMCs to multiple IH-promoting phenotypes, including proliferation,
migration, and inﬂammation (production ofmonocyte chemoattractant
protein-1, Guo et al., unpublished data), yet protects ECs against
cytokine-induced dysfunction. These favorable outcomes may be
plausibly rationalized based on the latest breakthroughs in research
on epigenetic mechanisms. Super-enhancers, or genomic DNA units
containing clustered enhancers (Pott and Lieb, 2015), have been discov-
ered to be key determinants of cell fate or cell state transition (Whyte
et al., 2013). They amass a large proportion of epigenetic factors includ-
ing BRD4,master transcription factors, mediators (e.g. Med1), enhancer
chromatin marks (e.g. H3K27Ac), as well as RNA polymerase II (Hnisz
et al., 2013). Super-enhancers are found to be associated with BRD4
at overactive genes in several pathologies, e.g. cancer progression
(Whyte et al., 2013; Loven et al., 2013), EC activation (Brown et al.,
2014), and cardiomyocyte hypertrophy (Anand et al., 2013). Uponpathogenic stimulation, super-enhancers re-assemble at a subset of
overactive genes promoting their transcription which drives cell state
transition (Brown et al., 2014). Importantly, transcription elongation
cannot be activated until BRD4 “reads” (or binds) histone acetyl-lysine
and then recruits p-TEFb which in turn phosphorylates and activates
RNA polymerase II (Shi and Vakoc, 2014). Thus BRD4 provides a sensi-
tive intervention target, blockade of which disrupts super-enhancers
and associated pathogenic cell state transition. It is therefore plausible
to propose that in our study JQ1(+) treatment might have preferen-
tially suppressed the expression of overactive genes involved in SMC
transition to a migratory/proliferative state and EC transition to a in-
ﬂammatory state, by breaking the assembly of BRD4/acetyl-histone/
super-enhancers. Our ongoing studies of ChIP sequencing and RNA
sequencing using SMCs are expected to revealmore target genes beyond
PDGF receptors that are critically regulated by BRD4 or the BET family. It
is noteworthy that c-Myc, amaster transcription factor recently found to
be the major target of BRD4 in cancer cells (Delmore et al., 2011), was
not altered in rat SMCs following JQ1(+) treatment (Guo et al., unpub-
lished data), highlighting a cell type speciﬁcity of BET regulations.
5. Study Limitations
Although we observed pronounced up-regulation of BRD4 in the
neointima of human vein and artery grafts versus normal vessels, the
Fig. 8. Prevention of inﬂammatory cytokine-induced vascular endothelial cell dysfunction by JQ1(+). A. TNFα or IL-1β-induced (20 ng/ml, 4 h) human aortic EC apoptosis, measured as
Caspase-3/7 activity, was prevented by pre-treatment with 100 nM JQ1(+) for 24 h. B. TNFα or IL-1β-induced (20 ng/ml, 4 h) inhibition of ECmigration was prevented by pre-treatment
with 100 nM JQ1(+) for 24 h. Quantiﬁcation:mean± SEM; n= 3; #P b 0.05 versus vehicle control; *P b 0.05 between the conditions in the absence and presence of JQ1(+). C. Images of
human aortic ECs 24 h after scratch. Dashed line marks the cell-free gap at 0 h after scratch. Quantiﬁed data are presented in B.
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that in diseased human vessels, which may limit the ability to extrapo-
late the current ﬁndings to outcomes in humans. In addition, an in vivo
test of the effect of JQ1(+) on the recovery of damaged endothelium
would lead tomore in-depth understanding of the therapeutic potential
of the BET-targeting strategy. It should also be noted that the siRNA
knockdown of BRD2 was inefﬁcient and may be insufﬁcient to rule
out functional effects of this protein. Thus further investigations are
warranted to delineate the speciﬁc function of BRD2 in SMC pathophys-
iology. Comparative studies to evaluate the contributions of all three
BET members in the development of neointima would assist the devel-
opment of optimal BET inhibitors for therapeutic applications.
6. Conclusion
This study demonstrates that IH can be abrogated via inhibition
of BET epigenetic reader activity. We have further identiﬁed that
the BET family controls the expression of PDGF receptors — the most
potent stimulant of the IH-promoting SMC transition to a migratory/
proliferative cell state. In light of the human relevance of these ﬁndings
and the recent progress that some BET inhibitors have entered clinical
trials, targeting BET bromodomains appears to be a promising strategy
for treating vascular diseases typiﬁed by IH.
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